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Objective: Most clinicians regard angioplasty with or without stent placement to be the treatment of choice for transplant
renal artery stenosis (TRAS). However, published results regarding its effectiveness are heterogeneous. The aim of this
study was to assess the safety and efﬁciency of TRAS endovascular therapy.
Methods: All cases of TRAS admitted for treatment in our unit from January 2009 to December 2012 were reviewed
retrospectively. The primary end point was the stenosis-free primary transplant renal artery patency. Secondary end points
were freedom from reintervention, graft survival, postoperative serum creatinine level, blood pressure evolution, and the
number of antihypertensive drugs pre- and postprocedure.
Results: A total of 17 patients (10 men, 7 women) presenting with TRAS were referred to our institution. During the early
post-transplantation process (<15 days), 35.2% of patients presented. The median time to presentation was 40 days. The
predominant presentation was graft function alteration (82.3%). Percutaneous balloon angioplasty was performed in ﬁve
patients (29.4%), while stenting was performed in the remaining 12 patients (70.6%). The stenosis-free primary patency
rate and freedom from reintervention rate were 76.5% and 88.2%, respectively. The median follow-up was 19.6 months
with 88.2% graft survival. There were no mortalities throughout the follow-up period. Serum creatinine levels decreased
signiﬁcantly from 186 mmol/L (range, 148-310 mmol/L) preoperatively to 160 mmol/L (range, 127-236 mmol/L at
discharge (P [ .0036). The glomerular ﬁltration rates increased from 32.1 mL/min (range, 21.4-45.8 mL/min) to
41.7 mL/min (range, 27.5-52.4 mL/min; P [ .004). Systolic and diastolic blood pressure varied from 140 mm Hg
(range, 137-157 mm Hg) and 75 mm Hg (range, 70-80 mm Hg), to 135 mm Hg (range, 130-147 mm Hg and 80 mm
Hg (range, 73-80 mm Hg), respectively (P [ .11 and P [ .36). The preoperative number of antihypertensive medi-
cations was 2 (range, 1-3) and remained unchanged (P [ .33).
Conclusions: The endovascular management of TRAS is safe and presents a high rate of technical success with low
morbidity. Its impact on serum creatinine levels is signiﬁcant in our experience. However, the blood pressure items do not
seem to improve postoperatively. (J Vasc Surg 2014;59:1058-65.)Transplant renal artery stenosis (TRAS) is a rare event
that might occur at any time during the postoperative
period and follow-up. The incidence of TRAS seems to
neighbor 0.8%, and it is a serious predictor of graft loss.1
There is still controversy regarding the potential beneﬁts
of endovascular treatment of these lesions in terms of graft
survival, improvement in renal function, and blood pres-
sure normalization. The aim of this study is to assess the
short- and midterm outcomes of TRAS angioplasty with
or without stenting based on a single-center experience.
METHODS
All patients were referred to our institution from other
medical establishments, mainly nephrology units, following
a clinical diagnosis of TRAS conﬁrmed by postoperative
Doppler ultrasonography. We performed a retrospectivethe Department of Vascular Surgery, Institut Mutualiste Montsouris.
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8review of all cases of TRAS treatment from January 2009
to December 2012, based on postoperative reports data-
base, and completed with data from the PMSI (Programme
Médicalisé des Systèmes d'Information) French national
database, where all admitted patients are registered.
We collected data concerning patients’ characteristics
(age, gender, comorbidities), organ donors’ characteristics,
type of anastomosis, clinical presentation, time to presenta-
tion, type of procedure (angioplasty with or without stent
placement, type and number of stents), early and late
outcomes, and serum creatinine levels and blood pressure
value before the procedure, at discharge, and at the latest
follow-up. We updated our information by contacting the
referent nephrologist of each patient.
Operative technique. All endovascular procedures
took place in the operating theater that is equipped with
OEC 9900 Elite mobile C-arm (GE Healthcare, Chalfont
St. Giles, Buckinghamshire, UK). The transplant renal
artery was implanted on the external iliac artery using an
end-to-side anastomosis in all treated patients. Under
local or general anesthesia, a percutaneous ultrasound-
guided retrograde femoral access, ipsilateral to the graft,
was performed using a 5F short sheath. At this stage, all
patients received intravenous heparin sodium (50 IU/kg).
A preliminary nonselective angiography was ﬁrst performed
in order to conﬁrm the diagnosis, rule out iliac obstructive
disease, and determine the orientation of the C-arm that
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generally through a 30 to 45 left rotation in the transverse
plane. When the stenosis was conﬁrmed, catheterization of
the renal artery was performed using a 0.035” or a 0.014”
guidewire and different-shaped catheters (5F Vanschie 1, 2,
or 3 catheters; Cook, Bloomington, Ind; and 5F Bern
catheter; Boston Scientiﬁc, Natick, Mass). Subsequently,
the balloon catheter and/or balloon-expandable monorail
stent system was inserted and deployed. Road-mapping
allowed minimum usage of contrast material. Stenosis
measurement was based on the ratio between the narrowed
segment and the following normal segment of the renal
artery. A stenosis was considered signiﬁcant when superior
to 70%, especially when ultrasound criteria were present
(allograft artery peak systolic velocity>2 m/s). Balloon and
stent size were chosen to match the diameter of the normal
adjacent segment of the renal artery. After deployment,
a completion angiography was performed. The femoral
artery hemostasis was obtained by manual compression.
Immediate postoperative follow-up was performed in
our unit, with close surveillance of clinical features (femoral
access, volume status, blood pressure, urine volume) and
biological tests (hemoglobin, serum creatinine level).
Discharge criteria were the absence of procedure-related
complications and decrease or stability of blood pressure
and serum creatinine levels. A Doppler ultrasonography
was performed before discharge. Further follow-up was
conducted by the referring nephrology unit. Doppler ultra-
sonography was also performed at 1 month, at 6 months,
and at any time during follow-up if recurrence was
suspected.
The primary end point was the stenosis-free primary
patency rate. Secondary end points were freedom from
reintervention, graft survival, renal function, blood pressure
evolution, and number of antihypertensive drugs.
Statistical analysis. Weused theKaplan-Meiermethod
to represent the patency rates. Continuous data were
expressed as medians with interquartile range (Q1-Q3). We
performed a paired two-sample Student t-test to compare
preoperative and postoperative levels of serum creatinine
and blood pressure. The number of antihypertensive medi-
cations was compared with use of the Wilcoxon rank test.
The software used for statistical analysis was StatView (SAS
Institute Inc). A probability value of .05 was the threshold of
statistical signiﬁcance.
RESULTS
A total of 17 patients were admitted in our institution
with a high clinical suspicion of TRAS and positive duplex
ultrasound ﬁndings, including allograft artery peak systolic
velocity of 270 (200-450) cm/sec. There were 10 men and
seven women, with a median age of 65 years (range,
55-68 years).
The etiology of the original renal disease was diabetic
nephropathy (n ¼ 5), hypertensive nephropathy (n ¼ 3),
hepato-renal or renal polykystosis (n ¼ 2), Berger disease
(n ¼ 2), systemic lupus (n ¼ 1); reno-vascular disease
(n ¼ 1), chronic interstitial nephropathy (n ¼ 1),nephroblastoma with bilateral nephrectomy (n ¼ 1), and
one unknown origin. The prerenal transplant median
systolic and diastolic blood pressure values were, respec-
tively, 150 mm Hg (range, 146-157 mm Hg) and
88 mm Hg (range, 82-97 mm Hg).
Clinical presentation was delayed graft function in ﬁve
cases, secondary graft function deterioration in nine cases,
acute hypertension in one case, acute pulmonary edema
in one case, and severe duplex abnormalities without clin-
ical dysfunction in one case.
Three patients received renal grafts from living donors,
while the 14 others received allografts from brain-deceased
patients. The patients’ characteristics are compiled in the
Table.
In all patients, end-to-side anastomosis with use of the
external iliac was performed.
The median time from renal transplantation to presen-
tation was 40 days (range, 15-90 days). Six patients
(35.2%) presented and were treated within the ﬁrst 2 weeks
after transplantation (Fig 1).
Onepatient had returned tohemodialysis at admission. In
all remaining patients, the nadir post-transplant serum creati-
nine level was 160mmol/L (range, 116-181mmol/L), while
the serum creatinine value at admission was 186 mmol/L
(range, 148-310 mmol/L).
The stenosis was located in the ostial (n ¼ 5), juxta-
ostial (n ¼ 7; Fig 2), middle (n ¼ 4), and divided (n ¼ 1)
segment of the allograft renal artery and on both renal
and external iliac arteries in three patients (Fig 3).
The stenosis was conﬁrmed by angiography in all
patients. In ﬁve patients (29%), only balloon angioplasty
was performed, including one kissing-balloon dilatation
technique for a stenosis of the allograft artery bifurcation.
The 12 other patients were stented using bare-metal
balloon-expandable monorail stent systems. Sixteen stents
were used: 13 Herculink Elite renal stent (Abbott
Vascular), 2 Monorail Liberte coronary stents (Boston
Scientiﬁc), and 1 Omnilink Elite stent (Abbott Vascular)
in an external iliac artery. The median stent diameter was
5 mm (range, 5-6 mm), and the median stent length was
15 mm (range, 12-18 mm). No intraoperative complica-
tions were observed.
In two patients, the obstacle was due to a kink of the
artery distal to the anastomosis and resolved after stenting.
All other patients presented with classic stenosis appearing
as linear reduction of the vessel lumen.
Early postoperative outcomes. Early postoperative
events (ie, prior to day 30) were marked by four early reste-
nosis (<day 30) visible on ultrasound examination: Three
occurred on stented arteries, one on a simply dilated artery.
Two restenosis were moderate, inducing peak systolic
velocities less than 200 cm/sec and did not require endo-
vascular revision, while one restenosis was signiﬁcant and
lead to stent deployment over a previously dilated non-
stented artery. Another restenosis was, in fact, a persistent
stenosis due to incomplete coverage of the lesion by the
stent, accompanied with proximal dissection that required
an additional bare-metal stent placement. All redo
Fig 1. Intraoperative angiography. A, Early post-transplantation distal stenosis of the renal transplant artery, at day 6.
B, Satisfactory diameter retrieval after stenting.
Table. Patients’ characteristics, presentation, and management
Patient
No.
Age,
years Gender Original renal disease
Living/
deceased
donor
Interval between
transplantation
and treatment Clinical presentation Type of procedure Complication
1 54 Male Renal polykystosis D 49 days Delayed graft function Angioplasty Restenosis
2 19 Female Bilateral nephrectomy L 15 days Secondary renal failure Angioplasty -
3 65 Male Berger disease L 12 days Secondary renal failure Stent placement Renal artery
dissectionþ
stent
misplacement
4 65 Male Diabetic nephropathy D 24 days Secondary renal failure Stent placement -
5 67 Male Diabetic nephropathy D 9 days Secondary renal failure Stent placement Restenosis
6 62 Female Reno-vascular disease D 16 days Delayed graft function Stent placement -
7 60 Female Hypertensive
nephropathy
D 75 days Secondary renal failure Stent placement -
8 66 Female Chronic interstitial
nephropathy
D 158 days Secondary renal failure Angioplasty -
9 61 Female Diabetic nephropathy L 40 days Secondary renal failure/
hemodialysis
Stent placement -
10 75 Male Diabetic nephropathy D 122 days None/Doppler
ultrasound ﬁndings
Stent placement -
11 44 Male Hepato-renal
polykystosis
D 90 days Delayed graft function Angioplasty -
12 41 Female Systemic lupus D 74 days Secondary renal failure Stent placement Restenosis
13 71 Male Hypertensive
nephropathy
D 10 years Acute pulmonary edema Angioplasty -
14 55 Male Berger disease D 6 days Delayed graft function Stent placement -
15 68 Male Diabetic nephropathy D 240 days Secondary renal failure Stent placement -
16 71 Male Undetermined D 15 days Delayed graft function Stent placement -
17 68 Female Hypertensive
nephropathy
D 12 days Severe hypertension Stent placement -
D, Deceased; L, living.
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success rate was 88.2% (15/17) when considering resteno-
sis events requiring redo intervention.
The serum creatinine level after endovascular treatment,
at discharge, was 160 mmol/L (range, 127-236 mmol/L).
There was a signiﬁcant decrease in serum creatinine levels
(P ¼ .0036). The glomerular ﬁltration rates increased
from 32.1 mL/min (range, 21.4-45.8 mL/min) to
41.7mL/min (range, 27.5-52.4mL/min; P¼ .004; Fig 4).The systolic blood pressure decreased from 140mmHg
(range, 137-157mmHg) before the procedure, to 135mm
Hg (range, 130-147 mm Hg) at discharge (Fig 5). This
result was not signiﬁcant (P ¼ .11). The mean diastolic
blood pressure was not signiﬁcantly different before the
procedure and at discharge, slightly increasing from
75 mm Hg (range, 70-80 mm Hg) to 80 mm Hg (range,
73-80 mmHg; P¼.36). There was no immediate modiﬁca-
tion of the number of antihypertensive drugs in all patients.
Fig 2. A, Postostial long stenosis of the renal transplant artery. B, Satisfactory result after stenting.
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primary patency and freedom from reintervention curves
are represented in Fig 6, a and b.
No postoperative deaths occurred. Two renal trans-
plants were extracted 10 and 22 months after the endovas-
cular procedure, because of persistent renal insufﬁciency in
the patient who had been under hemodialysis since the
early post-transplant period, and chronic rejection in the
other case. Of the remaining transplants, four suffered
from additional nonvascular renal disease that altered the
graft function: one graft tuberculosis, one lupic nephrop-
athy, one glomerulopathy with severe lesions of focal
segmental hyalinosis, and one graft function alteration after
multiple dehydration episodes.
The serum creatinine level in all patients that have kept
their graft was 180 mmol/L (range, 135-292 mmol/L) at
latest follow-up. Only two patients had a reduction of the
number of antihypertensive drugs by half. The median
number of antihypertensive drugs remained unchanged
with median two antihypertensive medications (range,
1-3) and no signiﬁcant difference when compared with
preoperative condition (P ¼ .33). Concerning the single
patient who presented with acute hypertension, the blood
pressure diminished from 165/85 mm Hg to 150/
75 mm Hg, and one antihypertensive drug was pursued
instead of bitherapy. The patients who underwent redo
stenting maintained the patency of the renal transplant
artery. None of the early managed patients (<day 15)
developed a pseudoaneurysm at the site of angioplasty or
stenting.The median follow-up was 19.6 months (range, 8.5-
24months), and themean follow-upwas 18.56 8.5months.DISCUSSION
This retrospective study highlights the safety of the
endovascular management of TRAS, including treatment
of early TRAS, its efﬁciency concerning cases presenting
with graft function alteration, the inconstant reduction of
mean blood pressure values, and the non-negligible rate
of restenosis, being, however, simply and successfully
managed.
TRAS is a serious complication of renal transplanta-
tion, with an incidence reaching 0.8%, with most cases
occurring during the ﬁrst 6 months and in elderly trans-
planted patients.1 Early appearing stenoses are mainly
due to traumatic intimal injury during harvesting or vessel
manipulation, kinking of the artery when it is longer than
the vein, or technical problems with the vascular suture,
while stenoses occurring later, sometimes in terms of
years, reﬂect allograft renal artery hyperplasia or renal
and/or iliac atherosclerotic evolution.2 Late and diffuse
stenosis might also reﬂect endothelial damage related to
immune response.3 In our series, the median time to
presentation was 40 days, and 13 (76.4%) patients pre-
sented before day 90. This result suggests that the vessel
stenosis was most probably related to a technical
problem.
Clinical indicators of TRAS are graft dysfunction and/
or new or refractory hypertension.
Fig 3. Intraoperative angiography. A, Severe iliac lesion probably resulting from clamp application, associated to juxta-
ostial transplant artery stenosis. B, Both lesions were successfully stented.
Fig 4. Evolution of serum creatinine levels (A) and glomerular ﬁltration rates (B) expressed as medians with inter-
quartile range. FU, Follow-up; RT, renal transplantation.
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for TRAS are peak systolic velocity higher than 200 cm/sec,
resistance index <0.5, and velocity gradient >2:1.4-6
Reported signiﬁcant risk factors for TRAS are delayed
graft function1,7,8 and cytomegalovirus infection.7-9 Other
risk factors are inconstantly signiﬁcant: expanded donor
criteria (mainly regarding age),1 obesity,8 and ischemicheart disease.1 The origin of the graft is also an uncertain
risk factor: a deceased donor is not signiﬁcantly correlated
with TRAS according to some series.1,7,10 On the other
hand, prevalence rates of TRAS in deceased donor trans-
plants have been reported to reach 4.1%, 4.5%, and
6.5%,11-13 compared with 0.3%, 0.8%, and 1.7% in living
related transplants.11,14,15
Fig 5. Evolution of systolic (A) and diastolic (B) blood pressure expressed as medians with interquartile range. FU,
Follow-up; RT, renal transplantation.
Fig 6. Kaplan-Meier curves for stenosis-free primary patency (a) and freedom from reintervention rates (b). The arrow
indicates the time where standard error (SE) exceeds 10%.
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must be the main indication of treatment. An isolated
Doppler ultrasonography examination showing proximal
stenosis of the allograft artery does not always imply clinical
consequence. Interestingly, a recent study describes
severely elevated velocities in nearly 45% of transplanted
patients (>400 cm/sec) with normal clinical course or
normalization of the peak systolic velocity in the majority
of cases without intervention. Only those with a persistent
elevated value of the peak systolic velocity were directed to
angiography, with time to angiography varying from
1 week to 4 months.16
Two therapeutic approaches are possible: revision
open surgery is actually considered as a rescue therapy
and is reserved for cases of unsuccessful angioplasty or
with severe complicated stenosis, because of the high re-
ported rate of signiﬁcant complications such as graft loss
(15% to 20%), ureteral injury, and reoperation.17 The
vast majority of TRAS cases are treated using an endovas-
cular approach, either by balloon angioplasty, or byprimary or secondary stenting, that typically address linear
short lesions relatively distal from the anastomosis site.
However, in spite of the lower effectiveness and the
higher risk of percutaneous transluminal angioplasty in
anastomotic lesions,17,18 many authors report an unevent-
ful treatment of stenosis at the anastomotic line6,19,20 with
a delay to percutaneous transluminal angioplasty of at
least 2 months post-transplantation.6 In our study, four
lesions were located at the anastomotic site, and 13
were distal to the anastomosis, with one hilar lesion
requiring a kissing-balloon technique. None of the anas-
tomotic dilatation procedures induced postoperative
complications, including those performed early after
transplantation (35%). In our opinion, the decision of
early TRAS endovascular management especially for anas-
tomotic lesions should take into account the patients’
post-transplant general condition and implies a vascular
surgeon performing the procedure in an operating room
in the presence of an anesthesiologist, after appropriate
patient installation.
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feasible, with a technical success rate frequently reported
between 89%5,11,21 and 100%,3,4,22 which is coherent
with the overall technical success rate of 88.2% in this
series. It is also a safe technique, with a speciﬁc complica-
tion rate varying in recent series from 0%3,4,6 to 5.5%.5,22
Peregrin et al noticeably report an overall complication
rate of 25.5% that includes medically managed groin hema-
toma, and intraoperatively stented iatrogenic renal dissec-
tion, all managed successfully without sequelae.
Restenosis is the main inherent complication of the
endovascular techniques, with no speciﬁcity regarding the
particular location at the renal transplant artery. Balloon
angioplasty alone entails a 10% to 56% restenosis
rate.7,11,14,18,23 This result seems to improve with stent
usage, with rates of restenosis following primary stenting
varying from 5.5%4 to 20%.23
In our series, four patients presented with duplex signs
of transplant artery stenosis during the early postoperative
period (ie, prior to day 30). One patient had been treated
with balloon angioplasty alone and was therefore subse-
quently stented. In the three remaining patients, TRAS
had been initially stented. The restenosis was conﬁrmed
but moderate in two patients, and was therefore medically
managed with good outcomes. In the remaining case, the
signs were in fact related to the same persistent proximal
stenosis because of an incomplete coverage of the lesion
by the stent. Consequently, the freedom from reinterven-
tion rate was 88.2%. No late restenosis was observed during
the available follow-up.
Effectiveness of angioplasty in terms of graft survival is
equivocal. Audard et al7 reported a long-term graft survival
signiﬁcantly higher in TRAS-free transplanted patients,
compared with the TRAS group, despite angioplasty. Hurst
et al stated that graft survival after TRAS was not signiﬁcantly
different in patients treated with angioplasty compared with
those without angioplasty. Conversely, multiple series4,24,25
report no difference in the survival curve of the grafts without
TRAS comparedwith thosewith stenting treatedwithTRAS.
Another ambiguity is found concerning endovascular treat-
ment effectiveness in improving hypertension and reducing
antihypertensive medication doses. Although we observe
a trend toward a positive impact on lowering systolic or dia-
stolic blood pressure and the number of drugs postopera-
tively, this is not statistically signiﬁcant in our series. This
may be due to the relatively small size of this series and the
fact that most patients have no signs of acute or novel hyper-
tension at admission. Some published series report signiﬁcant
decrease of the blood pressure values as well as the number of
antihypertensive drugs,4,22 while others rejoin our experi-
ence, obtaining nonsigniﬁcant change of those values.26,27
The impact on postoperative creatinine levels seems more
consensual, with a majority of reports citing signiﬁcant
decrease following angioplasty with or without stent place-
ment.3-6,11,22
Our study is limited by the small number of included
patients, the retrospective process, and the absence of
a control group of transplanted patients without TRAS,due to the fact that all treated patients were referred to
our center from external transplantation units.
CONCLUSIONS
The endovascular management of TRAS seems safe
and shows a high rate of technical success. Its effectiveness
on serum creatinine value seems almost constant, but the
impact on blood pressure evolution must be further inves-
tigated in larger series. One must keep in mind that the
ultimate end point is the graft survival. The latter presents
heterogeneous outcomes when the actual literature is
reviewed, in the absence of prospective controlled studies.
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